Navigation Links
Ovation further advances development pipeline with new phase III epilepsy study
Date:9/4/2007

clobazam brings new hope to the children and young adults who suffer from this devastating condition." For this patient population, there is an urgent need for novel therapies that help manage the disease, said lead study investigator Joan A. Conry, M.D., Professor of Neurology and Pediatrics in the Department of Neurology at Childrens National Medical Center in Washington, D.C. We know clobazam has an internationally well established safety and efficacy profile and if the results we have seen thus far are an indication of its potential in patients with LGS in the U.S., we may finally have a treatment that will fill an important unmet need.

Clobazam is one of the key products in OVATIONs CNS development program. The company is advancing its near-term pipeline on other fronts as well. In July 2007, the company initiated a clinical trial to evaluate a novel intravenous formulation of carbamazepine, a widely used oral antiepileptic drug, in adult patients with epilepsy. The launch of another oral anticonvulsant for rare and refractory epilepsies is anticipated next year.


'/>"/>
Contact: Nikki Nelson
nikki.nelson@edelman.com
312-565-2183
Edelman Public Relations
Source:Eurekalert

1

GOOD

Page: 1 2

Related medicine news :

1. Genetic innovation
2. Biocon To Shift Focus On Innovation To Accelerate Growth
3. IIT Delhi To Display Its Technological Innovations In Open House
4. Patent for Seminal RNAi innovation Cleared in Australia
5. Innovation Needed In The Field Of Diagnostics: Nair
6. A young scientist recognized for biomechanics innovations
7. Blood Safety, Supply, and Innovations Addressed at Conference
8. New Innovation in Clubfoot Treatment
9. Further support for use of statins in Alzheimer’s disease
10. Clinical Impact of Activity and Abdominal Pressure on Pelvic Floor Dysfunction Need to Be Further Analyzed
11. Doctor Accused Of Misdiagnosing 208 Patients: Further Investigation Ordered
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/9/2009)... New England Peptide, a Massac...ides and polyclonal antibodies for drug and vaccin...customers with alternative chemical solutions in t...eading New England Peptide,s strategic usage of ne...obert Hammer and Dr. Robert Hodges. , ...
(Date:1/8/2009)...OSTON, Jan. 8 The Allia...ngly opposes the new marketing campaigns by Wal-Ma... to provide free prescribed antibiotics to custome...they will actually lead to increased costs in the ...esistance. While the public,s need for affordable...
(Date:1/8/2009)...ALLAS, Jan. 8 A study released thi...are suffering from multiple chronic diseases shine... U.S. health care system to one that focuses on pr...Preventive Medicine, the leader in disease prevent...bin/prnh/20080506/NETU129LOGO ) , , The study...
(Date:1/8/2009)...alifornia Assembly Member Tom Torlakson Introduces...re-USNewswire/ -- Today, Lung Cancer Alliance-Ca...er Tom Torlakson (D-11th District) for his continu... funding for lung cancer research. For the third ... cancer research is being considered in the Califo...
Breaking Medicine News(10 mins):Health News:New Experts Help New England Peptide Combat Global Acetonitrile Shortage; Company Integrating Cost-Effective Chemical Solvent Alternatives 2Health News:New Experts Help New England Peptide Combat Global Acetonitrile Shortage; Company Integrating Cost-Effective Chemical Solvent Alternatives 3Health News:Antibiotics as Loss Leaders? 2Health News:U.S. Preventive Medicine: Chronic Disease Study Demonstrates Need for Focus on Primary and Secondary Prevention 2Health News:Lung Cancer Alliance Applauds New Legislation Funding Lung Cancer Research 2
...ty of Southern California in Los Angeles, study th...obese or overweight people and found// that the no...han their obese counterparts. The study that was ...an Dietetic Association stated that the compositio...
...s has gone against the general notion and has show...overstrain the emergency rooms// in hospitals in t...stated that most of the Hispanics were uninsured a...heir conditions worsen to the point where they wou...
...luding Tata Steel have joined hands with the Jhark... Trust to ensure medicare to the state's Below Pov...ed to contribute Rs 25 crore for the said purpose ...sar Group were expected to confirm their respectiv...
...stration (FDA) and Roxane Labs have issued a natio...re used in patients with severe// rheumatoid arthr...revent rejection. "It was discovered that a single...lot 558470A contained Methotrexate tablets USP 2.5...
Other Medicine News:Health News:Better Weight Management Can be Achieved By Increased Intake Of Fibre & Fruits 2
(Date:1/7/2009)... INDIANAPOLIS, Jan. 7 El...y that it received a complete response letter from...olanzapine long-acting,injection (LAI) for acute ...lts. Lilly is continuing to work with the agency o...A does not require any additional clinical trials ...
(Date:1/7/2009)...JING, Jan. 7 Tiantan Puhua Hospita...m ), the worldwide leader in using stem cells to e... today six new globally experienced additions to i...xpand the hospital,s treatment capabilities for gr...The six senior doctors include the distinguished D...
(Date:1/6/2009)... YORK, Jan. 6 The Micha... million to four industry research teams for pre-c...arkinson,s disease. , , The funding was awarded...Initiative. This program, first launched in 2006,... Parkinson,s research. TDI is part of MJFF,s foc...
(Date:1/5/2009)... DIEGO, Jan. 5 Cylene Pharmaceutic...I clinical trial of its oral CK2 protein kinase in...tumors, Castleman,s disease, or multiple myeloma. ...trial are determination of safety, tolerance and P...ate dose for Phase II trials. In addition, multipl...
Breaking Medicine Technology:FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 2FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 3FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 4FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 5FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 6Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients 2Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients 3Michael J. Fox Foundation Awards $2.7 Million to Four Industry Teams for Pre-Clinical Parkinson's Disease Research 2Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 2Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 3Labor 26 Medical Industry Give 56 25 of Prop 93 24 24 to Win Concessions in Health Care Legislation 8422 1Labor 26 Medical Industry Give 56 25 of Prop 93 24 24 to Win Concessions in Health Care Legislation 8422 2Labor 26 Medical Industry Give 56 25 of Prop 93 24 24 to Win Concessions in Health Care Legislation 8422 3TriWest Contributes 2415 000 to Kansas National Guard Fund 8420 1TriWest Contributes 2415 000 to Kansas National Guard Fund 8420 2Baxter Announces FDA Approval of GELFOAM 28R 29 Plus Hemostasis Kit 2253 1Baxter Announces FDA Approval of GELFOAM 28R 29 Plus Hemostasis Kit 2253 2Baxter Announces FDA Approval of GELFOAM 28R 29 Plus Hemostasis Kit 2253 3Baxter Announces FDA Approval of GELFOAM 28R 29 Plus Hemostasis Kit 2253 4Angiotech Submits 510 28K 29 To FDA For Its Innovative 5 FU CVC 2251 1Angiotech Submits 510 28K 29 To FDA For Its Innovative 5 FU CVC 2251 2Angiotech Submits 510 28K 29 To FDA For Its Innovative 5 FU CVC 2251 3Angiotech Submits 510 28K 29 To FDA For Its Innovative 5 FU CVC 2251 4Angiotech Submits 510 28K 29 To FDA For Its Innovative 5 FU CVC 2251 5
... Data presented at 12th Congress of European Hemat...e-FirstCall/ -- Alexion,Pharmaceuticals, Inc. toda...II studies examining Soliris(TM) (eculizumab) for ...ia (PNH) at the 12th,Congress of European Hematolo...on (EHA) in Vienna. These presentations,included: ...
...ARIS--(BUSINESS WIRE)--Jun 11, 2007 - Regulatory N...liminary data from the,ongoing phase III study for...relin do not support the expected sustainable bloo... in all patients.,Therefore, Ipsen has decided not...n the protocol. No safety concerns have,been obser...
Other Medicine Technology:Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 2Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 3Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 4Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 5Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 6Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 7Phase III Clinical Trial with 4-Month Long-Acting Formulation of,Triptorelin: Ipsen Decides Not to Perform Further Administration 2Phase III Clinical Trial with 4-Month Long-Acting Formulation of,Triptorelin: Ipsen Decides Not to Perform Further Administration 3
Nucleus divider with 1.25 mm tip and blade offset at a 60 degree angle is ideal for performing the "Phaco Chop" technique. Round knurled handle. Manufactured in titanium.
#2 10 mm hook. Flat serrated handle with polished finish. Overall length: 5.5 inches.
7 mm flattened hook. Flat serrated handle with polished finish. Overall length: 4.9 inches.
Left angled 5 mm blunt hook. Overall length: 9.9 inches.
Medicine Products: